HAKIM OGUNSANYA: Open Payments
NPI 1992166193 · MARRIOTTSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 18 payments from 8 companies in 2025. Trend: 2023 $175 · 2024 $89 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $126 |
| Lundbeck LLC | 5 | $113 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Janssen Pharmaceuticals, Inc | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
Products named: INGREZZA, COBENFY, REXULTI, ABILIFY ASIMTUFII, Auvelity, FANAPT, INVEGA SUSTENNA, CAPLYTA.
Industry payments across MD — which companies pay providers there.
